1
|
AL-ADL MENNA, YOUSSEF MAGDYM, EL-SEBAIE AHMED, REFAAT SHERIF, EL-SAID AFAF. The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients. Oncol Res 2024; 32:785-797. [PMID: 38560574 PMCID: PMC10972729 DOI: 10.32604/or.2024.047021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Accepted: 01/17/2024] [Indexed: 04/04/2024] Open
Abstract
Cytochromes P450 (CYPs) play a prominent role in catalyzing phase I xenobiotic biotransformation and account for about 75% of the total metabolism of commercially available drugs, including chemotherapeutics. The gene expression and enzyme activity of CYPs are variable between individuals, which subsequently leads to different patterns of susceptibility to carcinogenesis by genotoxic xenobiotics, as well as differences in the efficacy and toxicity of clinically used drugs. This research aimed to examine the presence of the CYP2B6*9 polymorphism and its possible association with the incidence of B-CLL in Egyptian patients, as well as the clinical outcome after receiving cyclophosphamide chemotherapy. DNA was isolated from whole blood samples of 100 de novo B-CLL cases and also from 100 sex- and age-matched healthy individuals. The presence of the CYP2B6*9 (G516T) polymorphism was examined by PCR-based allele specific amplification (ASA). Patients were further indicated for receiving chemotherapy, and then they were followed up. The CYP2B6*9 variant indicated a statistically significant higher risk of B-CLL under different genetic models, comprising allelic (T-allele vs. G-allele, OR = 4.8, p < 0.001) and dominant (GT + TT vs. GG, OR = 5.4, p < 0.001) models. Following cyclophosphamide chemotherapy, we found that the patients with variant genotypes (GT + TT) were less likely to achieve remission compared to those with the wild-type genotype (GG), with a response percentage of (37.5% vs. 83%, respectively). In conclusion, our findings showed that the CYP2B6*9 (G516T) polymorphism is associated with B-CLL susceptibility among Egyptian patients. This variant greatly affected the clinical outcome and can serve as a good therapeutic marker in predicting response to cyclophosphamide treatment.
Collapse
Affiliation(s)
- MENNA AL-ADL
- Division of Biochemistry, Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, 35511, Egypt
| | - MAGDY M. YOUSSEF
- Division of Biochemistry, Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, 35511, Egypt
| | - AHMED EL-SEBAIE
- Hematology Unit, Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura, 35511, Egypt
| | - SHERIF REFAAT
- Medical Oncology Unit, Oncology Center Mansoura University, Mansoura, 35511, Egypt
| | - AFAF EL-SAID
- Department of Genetics, Mansoura University Children’s Hospital, Mansoura, 35511, Egypt
| |
Collapse
|
2
|
Kassogue Y, Diakite B, Maiga M, Kassogue O, Konate I, Tamboura K, Diarra F, Diarra Z, Sawadogo MK, Goita Y, Sissoko SB, Sissoko AS, Guirou N, Dehbi H, Nadifi S, Bah S, Traore CB, Kamate B, Dao S, Dolo G. Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen. Pharmacogenet Genomics 2022; 32:219-225. [PMID: 35852913 PMCID: PMC7613628 DOI: 10.1097/fpc.0000000000000477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The main objective of this study was to evaluate the effect of CYP2B6 and CYP3A4 polymorphisms on the virological and immunologic responses of HIV patients. A total of 153 HIV-positive patients were enlisted for the study. PATIENTS AND METHODS Viral load and median CD4 T cell counts were evaluated at baseline and month 6 (M6). Samples were identified using TaqMan genotyping assays. RESULTS The AG in CYP2B6 rs2279343 was associated with VLS compared to homozygous AA. In the dominant model, the AG/GG genotypes were associated with VLS compared to the AA genotype. Moreover, in overdominant model, the AG genotype was associated with VLS compared to AA/GG. Regarding immunological response, only the AG in SNP rs2279343 CYP2B6 was associated with an increase in CD4 cell count between baseline and M6. In CYP2B6 rs3745274, the CD4 cell count at M6 was higher than that of baseline for GG carriers and for GT carriers. In CYP3A4 rs2740574, the TC carriers showed a higher median CD4 count at M6 compared to that of the baseline count, as well as for CC carriers. The best genotypes combination associated with CD4 cell count improvement were AA/AG in SNP rs2279343 and GG/GT in SNP rs3745274. CONCLUSION Our findings support the fact that CYP2B6 rs2279343 could help in the prediction of VLS and both SNPs rs3745274 and rs2279343 in CYP2B6 and CYP3A4 rs2740574 were associated with immune recovery in Malian HIV-positive patients.
Collapse
Affiliation(s)
- Yaya Kassogue
- Department of Anatomo-pathology, University Hospital of Point G
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
| | - Brehima Diakite
- Department of Anatomo-pathology, University Hospital of Point G
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
| | - Mamoudou Maiga
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
- Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA
| | - Oumar Kassogue
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
| | - Issa Konate
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
- Department of Infectious Diseases and Tropical Medicine, University Hospital of Point G
| | - Kadidiatou Tamboura
- Department of Infectious Diseases and Tropical Medicine, University Hospital of Point G
| | - Fousseyni Diarra
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
| | - Zoumana Diarra
- Center of Listening, Care, Animation, and Counseling for People Living With HIV
| | | | - Yaya Goita
- Department of Medical Biology and Anatomo-pathology, University Hospital, Mali Hospital
- Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako
| | - Sidi Boula Sissoko
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
- Department of Cytogenetics and Reproductive Biology, National Institute for Public Health Research
| | - Adama Seydou Sissoko
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
- Department of Neurology, University Hospital of Point G
| | - Nouhoum Guirou
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
- Institute of Tropical Ophthalmology of Africa, Bamako, Mali
| | - Hind Dehbi
- Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II
- Medical Genetics Laboratory, Ibn Rochd University Hospital Center, Casablanca, Morocco
| | - Sellama Nadifi
- Cellular and Molecular Pathology Laboratory, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II
- Medical Genetics Laboratory, Ibn Rochd University Hospital Center, Casablanca, Morocco
| | - Sekou Bah
- Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako
- Department of pharmacy, University Hospital of Point G, Bamako, Mali
| | - Cheick Bougadari Traore
- Department of Anatomo-pathology, University Hospital of Point G
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
| | - Bakarou Kamate
- Department of Anatomo-pathology, University Hospital of Point G
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
| | - Sounkalo Dao
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
- Department of Infectious Diseases and Tropical Medicine, University Hospital of Point G
| | - Guimogo Dolo
- Laboratory of Research and training on Molecular Pathologies, University Hospital of Point G
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako
| |
Collapse
|